{
  "docId": "019de517-75a1-7387-968b-d0dc513bf421",
  "docSlug": "e930bfcc8684afb6f5a4dd5442b5166d",
  "documentTitle": "Ocuphire Pharma | Investor Presentation Deck | 42 slides",
  "authorId": "ocuphire-pharma",
  "authorName": "Ocuphire Pharma",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-11-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 5,
  "pageCount": 42,
  "prevPage": 4,
  "nextPage": 6,
  "slideType": "key_messages",
  "function": "summarize",
  "density": "dense",
  "nDataPoints": 1,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de517-75a1-7387-968b-d0dc513bf421/5",
  "deckHref": "/decks/019de517-75a1-7387-968b-d0dc513bf421",
  "deckJsonHref": "/decks/019de517-75a1-7387-968b-d0dc513bf421.json",
  "deckAnchorHref": "/decks/019de517-75a1-7387-968b-d0dc513bf421#slide-5",
  "components": [
    {
      "bbox": {
        "h": 0.02,
        "w": 0.069,
        "x": 0.047,
        "y": 0.94
      },
      "kind": "image",
      "text": "Ocuphire",
      "attrs": {},
      "subkind": "logo",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5bdbfaa0-a484-44ea-b77f-5fb5d8ce04ae",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.21,
        "w": 0.899,
        "x": 0.068,
        "y": 0.21
      },
      "kind": "list",
      "text": "Late-Stage Clinical Candidate for Retinal Diseases Represents Multi-Billion Dollar Opportunity\nAPX3330: Paradigm Changing, Non-invasive, Safe Oral Tablet for millions of NPDR patients that are currently left untreated\nRef-1, a novel, dual target (angiogenesis and inflammation) for retinal diseases\nZETA-1 Phase 2 showed APX3330 prevented or slowed progression of Diabetic Retinopathy (DR)\nSuccessful EOP2 meeting with the FDA and a Special Protocol Assessment (SPA) to be submitted",
      "attrs": {},
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "498d8797-1a11-44f1-b7ce-32c9abe5811f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.025,
        "w": 0.899,
        "x": 0.068,
        "y": 0.849
      },
      "kind": "list",
      "text": "Experienced Retina Drug Development Team to Advance APX3330 into Phase 3",
      "attrs": {},
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8d0f7b4e-c68f-4998-b1b0-1f8a57f8dae5",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.239,
        "w": 0.899,
        "x": 0.068,
        "y": 0.524
      },
      "kind": "list",
      "text": "Phentolamine Ophthalmic Solution 0.75% (POS) for Refractive Disorders\nGlobal license agreement with Viatris to fund all development and commercialization for phentolamine indications:\nRYZUMVI™ (Phentolamine Ophthalmic Solution) 0.75% for the treatment of pharmacologically-induced mydriasis received FDA approval in September 2023\nApproval triggered $10M milestone payment\nPresbyopia and Dim Light Disturbances currently in Phase 3",
      "attrs": {},
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "94b2ab13-4f40-4a91-97fd-f5e5b60a6830",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.025,
        "w": 0.23,
        "x": 0.047,
        "y": 0.06
      },
      "kind": "title",
      "text": "Corporate Highlights",
      "attrs": {},
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "195489ee-e715-4328-8eef-66311c5339ae",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "List presentation",
      "slug": "list-presentation",
      "agent": null,
      "layer": "slide",
      "matchId": "389fc486-7619-4875-8fda-a66eca46ddf7",
      "evidence": "list/bullet: Late-Stage Clinical Candidate for Retinal Diseases Represents Multi-Billion Dollar Opportunity",
      "confidence": 0.7
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 5,
      "from": 1,
      "beatId": "84e4008d-7221-45f0-9cd1-2bf80e7c9928",
      "arcName": "The Consultant's Gambit",
      "arcSlug": "consultants-gambit",
      "beatName": "Situation & Context",
      "beatSlug": "consultants-gambit-situation-context",
      "evidence": "Slides 1-5 provide an overview of Ocuphire Pharma and its pipeline",
      "position": 0,
      "confidence": 0.8,
      "parentBeatName": "Setup",
      "parentBeatSlug": "setup"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}